May 16 May 16 1-2 Punch: PD-L1 x 4-1BB et al.: Dual MOA or simply conditional bsAb ? Natasa Obermajer
Jan 13 Jan 13 Next generation therapeutic mAb: Does Fc-engineering translate into clinical efficacy Natasa Obermajer
Sep 14 Sep 14 Predicting the Efficacy and Outcome of I-O Therapies: Between Avatars, Ancers and Algorithms Natasa Obermajer
Apr 12 Apr 12 Oncolysis + Antitumor&Antiviral Immunity = Success of Oncolytic Virotherapy Natasa Obermajer
